DE1234229B - Process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid and its acid addition and quaternary ammonium salts - Google Patents
Process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid and its acid addition and quaternary ammonium saltsInfo
- Publication number
- DE1234229B DE1234229B DES94911A DES0094911A DE1234229B DE 1234229 B DE1234229 B DE 1234229B DE S94911 A DES94911 A DE S94911A DE S0094911 A DES0094911 A DE S0094911A DE 1234229 B DE1234229 B DE 1234229B
- Authority
- DE
- Germany
- Prior art keywords
- thienyl
- glycolic acid
- acid
- ethanol
- quaternary ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 18
- 239000002253 acid Substances 0.000 title claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 title claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- -1 alkyl radicals Chemical class 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 11
- 229930003347 Atropine Natural products 0.000 description 9
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 9
- 229960000396 atropine Drugs 0.000 description 9
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960001789 papaverine Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- IMCSZGFLUYCDOG-UHFFFAOYSA-N 2-cyclohexyl-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1CCCCC1 IMCSZGFLUYCDOG-UHFFFAOYSA-N 0.000 description 2
- XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 229960002028 atropine sulfate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- GVWMHLCBIUIASU-UHFFFAOYSA-N 1-chloro-n,n-dimethylethanamine Chemical compound CC(Cl)N(C)C GVWMHLCBIUIASU-UHFFFAOYSA-N 0.000 description 1
- JKWQNZHDFGTRMZ-UHFFFAOYSA-N 2-cyclopentyl-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1CCCC1 JKWQNZHDFGTRMZ-UHFFFAOYSA-N 0.000 description 1
- HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010037218 Psychopathic personality Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Verfahren zur Herstellung von Aminoalkylestern der Thienyl-3-glykolsäure sowie ihren Säureanlagerungs- und quaternären Ammoniumsalzen Gegenstand der Erfindung ist ein Verfahren zur Herstellung von Aminoalkylestern der Thienyl-3-glykolsäure sowie deren Anlagerungssalzen mit pharmakologisch geeigneten anorganischen und organischen Säuren und ihren quaternären Ammoniumsalzen.Process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid and their acid addition salts and quaternary ammonium salts are the subject of the invention is a process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid as well as their addition salts with pharmacologically suitable inorganic and organic Acids and their quaternary ammonium salts.
Die Verfahrensprodukte, die in ihrer racemischen oder optisch aktiven Form vorliegen - können, entsprechen der allgemeinen Formel in der R1 der Cyclopentyl- oder Cyclohexylrest, R'2 ein Wasserstoffatom oder die Methylgruppe, f2 = 1 oder 2, R3 und R4 Wasserstoffatome oder Alkylreste mit 1 bis 4 Kohlenstoffatomen oder den Benzylrest bedeuten oder R3 und R4 zusammen mit dem Stickstoffatom einen Pyrrolidin-, Piperidin-, Morpholin- oder einen Azacycloheptanrest bilden.The products of the process, which can be in their racemic or optically active form, correspond to the general formula in which R1 is the cyclopentyl or cyclohexyl radical, R'2 is a hydrogen atom or the methyl group, f2 = 1 or 2, R3 and R4 are hydrogen atoms or alkyl radicals with 1 to 4 carbon atoms or the benzyl radical, or R3 and R4 together with the nitrogen atom are a pyrrolidine , Piperidine, morpholine or an azacycloheptane residue.
Die Verfahrensprodukte wirken, wie an Hand der nachfolgend angegebenen Tests nachgewiesen wird krampflösend (M a g n u s; Arch. d. ges. Physiologie, 1905, Bd. 108, S. 1 bis 71); antiulcerös (H a n s o n und B r o d i e, J. Appl. Physiol., 1960, Bd. 15, S.291, 294); lokalanästhetisch (M o u k h t a r , C. R. Soc. Biol. Paris, 1909, Bd. 61, S. l87); und beruhigend (B o i s s i e r und Mitarbeiter, Medicina Experimentalis, 1960, Bd. 3, S. 1, 81, 84).The products of the process have an antispasmodic effect, as demonstrated by the tests given below (M agnus; Arch. D. Ges. Physiologie, 1905, Vol. 108, pp. 1 to 71); antiulcer (Hanson and Rodie, J. Appl. Physiol., 1960, vol. 15, p.291, 294); local anesthetic (M oukht ar, CR Soc. Biol. Paris, 1909, vol. 61, p. 187); and reassuring (B oissi er and coworkers, Medicina Experimentalis, 1960, vol. 3, pp. 1, 81, 84).
Außerdem wurde auf Grund der bisherigen klinischen Beobachtungen eine psychodysleptische Wirkung festgestellt.In addition, based on previous clinical observations, a psychodysleptic effect noted.
Die Verfahrensprodukte erhält man in an sich bekannter Weise dadurch, daß man z. B. Thienyl-3-glykolsäuren der allgemeinen Formel in der R1 die angegebene Bedeutung hat, als Racemat oder nach der Trennung in die rechtsdrehende und linksdrehende Form mit einem Aminoalkylhalogenid der allgemeinen Formel in der R2, R3 und R4- die angegebene Bedeutung haben, kondensiert, wobei man die Halogenide der Aminoester erhält. Die Kondensation känn in einem wasserfreien organischen Lösungsmittel, insbesondere in Isopropanol, unter Erhitzen unter Rückfluß erfolgen.The process products are obtained in a manner known per se in that z. B. Thienyl-3-glycolic acids of the general formula in which R1 has the meaning given, as a racemate or after separation into the dextrorotatory and levorotatory form with an aminoalkyl halide of the general formula in which R2, R3 and R4- have the meaning given, condensed, the halides of the amino esters being obtained. The condensation can take place in an anhydrous organic solvent, in particular in isopropanol, with heating under reflux.
Zweckmäßig erhitzt man ein Gemisch aus äquimolaren Mengen der Thienyl-3-glykolsäure und des Aminoalkylchlorids in Isopropanol 15 bis 20 Stunden unter Rückfluß, destilliert dann das Lösungsmittel unter vermindertem Druck ab und kristallisiert den Rückstand aus einem oder mehreren organischen Lösungsmitteln um. Bei der Umsetzung der Thienyl-3-glykolsäuren mit dem Aminoalkylhalogenid kann in bestimmten Fällen an Stelle der Säure auch eines ihrer Salze, insbesondere das Natrium-, Kalium- oder Silbersalz, verwendet werden.A mixture of equimolar amounts of thienyl-3-glycolic acid is expediently heated and the aminoalkyl chloride in isopropanol under reflux for 15 to 20 hours, distilled then the solvent is removed under reduced pressure and the residue crystallizes from one or more organic solvents. In the implementation the thienyl-3-glycolic acids with the aminoalkyl halide can in certain cases in place of the acid also one of its salts, in particular the sodium, potassium or Silver salt, can be used.
Die folgenden Beispiele erläutern das erfindungsgemäße Verfahren. Beispiel 1 Cyclohexylthienyl-3-glykolsäure (7,2g) und Dimethylaminochloräthan (3,2g) werden 17 Stunden in 70 ccm wasserfreiem Isopropanol unter Rückfluß erhitzt. Das Isopropanol wird bei einem Druck von 50 mm bei 50°C abdestilliert. Der Rückstand wird durch Umkristallisation aus einem Äthanol-Äthyläther-Gemisch gereinigt. Man erhält farblose Kristalle vom F. 160°C.The following examples explain the process according to the invention. Example 1 Cyclohexylthienyl-3-glycolic acid (7.2g) and dimethylaminochloroethane (3.2g) are refluxed for 17 hours in 70 cc of anhydrous isopropanol. That Isopropanol is distilled off at 50 ° C. under a pressure of 50 mm. The residue is purified by recrystallization from an ethanol-ethyl ether mixture. Man receives colorless crystals with a melting point of 160 ° C.
Die Cyclohexylthienyl-3-glykolsäure sowie deren Methylester war auf folgendem Weg hergestellt worden: Man erhitzt das nach A. J. S p e z i a 1 e und H. W. F r a z i e r (Journ. Ord. Chem., 1961, Bd. 26, S. 3176) hergestellte Diäthylamid der Cyclohexylglyoxylsäure (142 g) 30 Stunden in wäßriger Salzsäure (1420 ccm HCI + 3200 ccm H20) unter Rückfluß. Das Produkt wird mit Äthyläther extrahiert und das Lösungsmittel aus dem Extrakt abgedampft. Kp.i,;: 115 bis 120°C; farblose Kristalle vom F. 53'C.The cyclohexylthienyl-3-glycolic acid and its methyl ester had been prepared in the following way: The diethylamide prepared according to AJ S pezia 1e and HW F razier (Journ. Ord. Chem., 1961, Vol. 26, p. 3176) is heated Cyclohexylglyoxylic acid (142 g) in aqueous hydrochloric acid (1420 cc HCl + 3200 cc H20) under reflux for 30 hours. The product is extracted with ethyl ether and the solvent is evaporated from the extract. Bp: 115 to 120 ° C; colorless crystals from F. 53'C.
Eine Ätherlösung der Cyclohexylglyoxylsäure (37 g) wird mit einer Ätherlösung von Thienyl-3-lithium versetzt, das aus Lithium (11 g), n-Butylbromid (83g) und 3-Bromthiophen (54g) erhalten worden war. Man erhält farblose Kristalle der Cyclohexylthienyl-3-glykolsäure vom F. 162°C, die in Äther und Äthanol löslich sind. Der durch Umsetzung mit Diazomethan hergestellte, in Form farbloser Kristalle erhaltene Methylester schmilzt bei 89°C. Beispiel 2 Nach dem Verfahren des Beispiels 1 erhält man bei Umsetzung der Cyclopentylthienyl-3-glykolsäure mit fl-Dimethylaminochloräthan das Hydrochlorid des Cyclopentylthienyl - 3 - glykolsäure - Et - dimethylamino-äthylesters, das nach der Kristallisation aus Äthanol bei 182°C schmilzt.An ether solution of cyclohexylglyoxylic acid (37 g) is mixed with an ether solution of thienyl-3-lithium obtained from lithium (11 g), n-butyl bromide (83 g) and 3-bromothiophene (54 g). Colorless crystals of cyclohexylthienyl-3-glycolic acid with a melting point of 162 ° C. which are soluble in ether and ethanol are obtained. The methyl ester prepared by reaction with diazomethane and obtained in the form of colorless crystals melts at 89.degree. Example 2 Following the procedure of Example 1 is obtained upon reaction of Cyclopentylthienyl-3-glycolic acid with fl-Dimethylaminochloräthan the hydrochloride of Cyclopentylthienyl - 3 - glycolic acid - Et - dimethylamino-ethyl ester which melts, after crystallisation from ethanol at 182 ° C.
Die dazu benötigte Cyclopentylthienyl-3-glykolsäure war wie folgt hergestellt worden Das in wasserfreiem Äther (400 ccm) aus Cyclopentylbromid (200 g) und Magnesium (33,2 g) erhaltene Cyclopentylmagnesiumbromid gibt man bei -20°C zu einer Lösung von N,N-Diätlayläthylcarbamat (180 g) in Äther (50 ccm). Man läßt die Temperatur innerhalb einer Stunde auf -5'-C ansteigen und hydrolysiert dann mit wäßriger Essigsäure. Darauf extrahiert man mit Äthyläther und destilliert unter Vakuum. Man erhält bei einem Druck von 15 mm bei 130 bis 150'C das N,N-Diäthylamid der Cyclopentylgiyoxylsäure, das mit N,N-Diäthyläthylcarbamat verunreinigt ist. Das Gemisch (157 g) wird durch 17stündiges Erhitzen unter Rückfluß in Wasser (3 Liter) und Salzsäure (1,2 Liter) hydrolysiert. Darauf wird mit Äther extrahiert und unter Vakuum destilliert. Kp. 125°C. Farblose hygroskopische Kristalle (F. 54=C), die bei 0,01 mm sublimieren.The cyclopentylthienyl-3-glycolic acid required for this was prepared as follows: The cyclopentylmagnesium bromide obtained in anhydrous ether (400 ccm) from cyclopentyl bromide (200 g) and magnesium (33.2 g) is added at -20 ° C to a solution of N, N-dietary ethyl carbamate (180 g) in ether (50 cc). The temperature is allowed to rise to -5'-C within an hour and then hydrolyzed with aqueous acetic acid. It is then extracted with ethyl ether and distilled under vacuum. Is obtained at a pressure of 15 mm at 130 to 150 'C, the N, N-diethylamide of Cyclopentylgiyoxylsäure which is contaminated with N, N-Diäthyläthylcarbamat. The mixture (157 g) is hydrolyzed by refluxing in water (3 liters) and hydrochloric acid (1.2 liters) for 17 hours. It is then extracted with ether and distilled under vacuum. Bp 125 ° C. Colorless hygroscopic crystals (F. 54 = C) that sublime at 0.01 mm.
Man versetzt die Cyclopentylglyoxylsäure (22 g) mit einer Lösung von Thienyl-3-lithium, das aus 3-Bromthiophen (41 g), Lithium (4,4 g) und n-Butylbromid (43 g) erhalten wurde. Man erhält farblose Kristalle der Cyclopentylthienyl-3-glykolsäure, die in Äthyläther und Äthanol löslich sind (F. 140'C).The cyclopentylglyoxylic acid (22 g) is mixed with a solution of Thienyl-3-lithium, which consists of 3-bromothiophene (41 g), lithium (4.4 g) and n-butyl bromide (43 g) was obtained. Colorless crystals of cyclopentylthienyl-3-glycolic acid are obtained, which are soluble in ethyl ether and ethanol (F. 140'C).
Nach dem Verfahren des Beispiels 1 oder 2 erhält man ferner die Hydrochloride
der in der nachfolgenden Tabelle angegebenen Verfahrensprodukte
Die LDSo wurde nach der Methode von M i 1 1 e r und T a i n t e r ermittelt. In der nachfolgenden Tabelle bedeutet IVM die intravenöse Injektion bei Mäusen, IPM die intraperitoneale Injektion bei Mäusen, POM die perorale Verabreichung an Mäuse und POR die perorale Verabreichung an Ratten.The LDSo was developed according to the method of M i 1 1 e r and T a i n t e r determined. In the table below, IVM means intravenous injection at Mice, IPM the intraperitoneal injection in mice, POM the oral administration to mice and POR to oral administration to rats.
Die spasmolytische Wirkung wurde in folgender Weise am Zwölffingerdarm der Ratte ermittelt: Die Atropinwirkung gegenüber der Wirkung von Acetyl-f-methylcholin, wobei als Einheit die Wirkung von Atropinsulfat zugrunde gelagt wurde.The spasmolytic effect was observed on the duodenum in the following way the rat determined: the atropine effect compared to the effect of acetyl-f-methylcholine, whereby the effect of atropine sulfate was taken as the basis.
Die Papaverinwirkung gegenüber der Wirkung von Bariumchlorid, wobei als Einheit die Wirkung von Papaverinhydrochlorid zugrunde gelegt wurde.The action of papaverine versus the action of barium chloride, whereby the unit was based on the effect of papaverine hydrochloride.
Die Infiltrationsanästhesie wurde nach der Methode von M o u k h t a r (C. R. Soc. Biol., 1909, Bd.61, S.187) bestimmt, wobei als Einheit die Wirkung von 1 o/oigem Procainhydrochlorid zugrunde gelegt wurde.The infiltration anesthesia was carried out according to the method of M o u k h t a r (C. R. Soc. Biol., 1909, vol. 61, p. 187) determined, the unit being the effect of 1% procaine hydrochloride was taken as the basis.
Die »Geschwür - zusammenziehende Wirkung« (ulcere de contrainte) wurde nach der Methode von H a n s o n und B r o d i e (J. of appl. Physiol., 1960, Bd. 15, S.291) bestimmt, wobei als Einheit die Wirkung von 24 mg/kg Atropinsulfat zugrunde gelegt wurde.The "ulcer - contracting effect" (ulcere de contrainte) was determined according to the method of Hanson and Rodie (J. of appl. Physiol., 1960, vol. 15, p.291), the unit being the effect of 24 mg / kg atropine sulfate was used.
Die Wirkung gegen Gelenkschmerzen wurde in der Weise ermittelt, daß man die Produkte lokal in die Tibia tarsale einspritzte, die zuvor durch Injektion von 10%igem Silbernitrat schmerzhaft gemacht worden war. Die das Auftreten von Schmerzen verhindernden Produkte sind mit (+) gekennzeichnet.The effect against joint pain was determined in such a way that the products were injected locally into the tibia tarsal, previously by injection had been made painful by 10% silver nitrate. The the appearance of pain preventing products are marked with (+).
Der »Kamintest« (test de la cheminee) wurde nach der Methode von B o i s s i e r , T a r d y und D i v e r r e s (Medie. Exper., 1960, Bd. 3, S. 1 bis 81) durchgeführt. Der »Zugfadentest« (test du fil de traction) wurde nach der Methode von C o u r v o i s i e r und J u -1 o u (J. chim. exper. psychopath., 1956, Bd. 17, S.25) ermittelt, wobei die erhaltenen Ergebnisse als ED5o ausgedrückt sind.The "chimney test" (test de la cheminee) was carried out according to the method of B oissier, Tardy and Diverres (Medie. Exper., 1960, vol. 3, pp. 1 to 81). The "Zugfadentest" (test du fil de traction) was determined by the method of C ourvoisier and J u -1 ou (J. chim. Exper. Psychopath., 1956, vol. 17, p.25), the results obtained are expressed as ED5o.
Der »Test zur Feststellung des Erkundungsdrangs« der Maus (test de Factivit@ exploratrice) wurde nach der Methode von B o i s s i e r und S i m o n (Therapie, 1962, Bd. 17, S. 1225) durchgeführt. Die Produkte, die zu einer Unterbindung dieser Eigenschaft führten, wurden mit (-r) bezeichnet.The "test to determine the urge to explore" of the mouse (test de Factivit @ exploratrice) was based on the method of B o i s s i e r and S i m o n (Therapy, 1962, vol. 17, p. 1225). The products that lead to a ligation this property were denoted by (-r).
Die Hemmung der elektrischen Stimulation des Vagus wurde an der mit Urethan narkotisierten Ratte bestimmt, wobei Atropin als Einheit zugrunde gelegt wurde.The inhibition of electrical stimulation of the vagus was at the with Urethane anesthetized rat was determined using atropine as a unit became.
Die Wirkung auf den arteriellen Blutdruck und der Antagonismus gegenüber Acetylcholin wurde an narkotisierten Ratten bestimmt. Die Verbindungen, die zu einem Uberdruck führten, wurden mit (---) und die zu einem Unterdruck führenden Verbindungen wurden mit (-) bezeichnet. Diejenigen Verbindungen, die den durch Acetylcholin verursachten Unterdruck verringerten, sind mit (-) und diejenigen, die ihn nicht modifizieren, mit (-) bezeichnet.The effect on arterial blood pressure and the antagonism opposite Acetylcholine was determined in anesthetized rats. The connections that lead to a Overpressure were indicated with (---) and the connections leading to underpressure were marked with (-). Those compounds that caused the acetylcholine Reduced negative pressure are marked with (-) and those who do not modify it, marked with (-).
Die Vertiefung der Narkose wurde durch Ermittlung der Fähigkeit von Tieren, die gerade aus einem Barbitursäureschlaf erwachten (Hexabarbital, 100 mg/kg intraperitoneal), nach der Verabreichung der Verbindungen gemäß der Erfindung wieder einzuschlafen, untersucht. Die erhaltenen Ergebnisse sind als ED5o ausgedrückt.The deepening of anesthesia was determined by determining the ability of Animals that have just awakened from sleep with barbituric acid (hexabarbital, 100 mg / kg intraperitoneally), again after administration of the compounds according to the invention to fall asleep, examined. The results obtained are expressed as ED50.
Der Open-Field-Test wurde nach der Methode von B o i s s i e r in »Therapie«, 1961, Bd. 2, S. 278 bis 286, durchgeführt. Mit (rt) wurden die Tiere bezeichnet, die eine gedämpfte Verhaltensweise bei der Untersuchung zeigten.The open field test was carried out according to the method of B o i s i e r in "Therapy", 1961, Vol. 2, pp. 278-286. With (rt) the animals became that showed a subdued behavior during the examination.
Die Ergebnisse der pharmakologischen Untersuchungen sind in der nachfolgenden
Tabelle zusammengestellt
Besonders interessante Verbindungen sind der ß-Pyrrolidinoäthylester der a-Cyclopentyl-a-thienyl-3-glykolsäure (Beispiel 5), die ß-Diäthylaminoäthylester (Beispiel 15), der (3-Pyrrolidino-äthylester (Beispiel 17), der ß-Pyrrolidino-a-methyläthylester (Beispiel 21), der y - Dimethylaminopropylester (Beispiel 23) und der y-Diäthylaminopropylester (Beispiel 24) der a-Cyclohexyl-a-thienyl-3-glykolsäure.Particularly interesting compounds are the ß-pyrrolidinoethyl ester of a-cyclopentyl-a-thienyl-3-glycolic acid (Example 5), the ß-diethylaminoethyl ester (Example 15), the (3-pyrrolidino-ethyl ester (Example 17), the ß-pyrrolidino α-methylethyl ester (Example 21), the γ-dimethylaminopropyl ester (Example 23) and the γ-diethylaminopropyl ester (Example 24) of α-cyclohexyl-α-thienyl-3-glycolic acid.
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR959367A FR1402863A (en) | 1964-01-04 | 1964-01-04 | New derivatives of alpha-thienyl-3 glycolic acid |
| FR969102A FR3409M (en) | 1964-01-04 | 1964-03-27 | Medicinal product based on α-thienyl-3 glycolic acid derivative. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1234229B true DE1234229B (en) | 1967-02-16 |
Family
ID=26205217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DES94911A Pending DE1234229B (en) | 1964-01-04 | 1965-01-02 | Process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid and its acid addition and quaternary ammonium salts |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE1234229B (en) |
| FR (1) | FR1402863A (en) |
| GB (1) | GB1062070A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562267A (en) * | 1980-07-28 | 1985-12-31 | Pfizer Inc. | Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones |
-
1964
- 1964-01-04 FR FR959367A patent/FR1402863A/en not_active Expired
- 1964-12-31 GB GB53041/64A patent/GB1062070A/en not_active Expired
-
1965
- 1965-01-02 DE DES94911A patent/DE1234229B/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR1402863A (en) | 1965-06-18 |
| GB1062070A (en) | 1967-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1670616C3 (en) | 14-hydroxydihydronormorphine compounds and processes for their preparation | |
| DE69231854T2 (en) | SUBSTITUTED (S) -3-PHENYLPIPERIDINE DERIVATIVES, THEIR PRODUCTION AND THE USE THEREOF AS DOPAMINE AUTORECEPTOR ANTAGONISTS | |
| DE69813839T2 (en) | USE OF N, N-BIS (PHENYLCARBAMOYLMETHYL) DIMETHYLAMMONIUM CHLORIDE AND DERIVATIVES THEREOF FOR THE TREATMENT OF CHRONIC PAIN | |
| DE2016667B2 (en) | 4- (DIPHENYLMETHYLEN) -PIPERIDINE, THE METHOD OF MANUFACTURING THEM AND THE MEDICINAL PRODUCTS CONTAINING THESE | |
| DE69633943T2 (en) | Morphine derivatives with analgesic properties | |
| DE2225245B2 (en) | (b.e) -Dibenzoxepin-l l-spiro-2 '- (l'3'-dioxolane) derivatives, processes for their preparation and pharmaceuticals containing them | |
| CH392542A (en) | Process for the preparation of basic amides | |
| DE2851416A1 (en) | 2- (4-BIPHENYLYL) -N- (DIETHYLAMINOALKYL) - PROPIONAMIDES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THESE | |
| DE69918046T2 (en) | Novel basic derivatives of benz (e) isoindol-1-ones and pyrrolo (3,4-c) quinolin-1-ones with 5-HT3 antagonist activity, their production and their therapeutic use | |
| DE1234229B (en) | Process for the preparation of aminoalkyl esters of thienyl-3-glycolic acid and its acid addition and quaternary ammonium salts | |
| DE2650876A1 (en) | NEW QUINUCLIDINE | |
| DE2513136C3 (en) | N- (1-Benzylpiperid-4-yl) -benzamides, process for their preparation and pharmaceutical preparations containing them | |
| DE1289849B (en) | 3- (Dibenzo [a, d] -1, 4-cycloheptadien-5-yloxy) -nortropane and process for its preparation | |
| DE2931319A1 (en) | 6-METHOXY-2-ACETYLNAPHTHALINOXIM DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME | |
| DE1518311B1 (en) | N- (2-Diaethylaminoaethyl) -2-methoxy-3,4- or 4,5-methylenedioxybenzamide and their pharmacologically non-toxic acid addition salts | |
| DE2240211A1 (en) | FLUORUBSTITUTED 3- (METHYLAMINO) - AND 3- (DIMETHYLAMINO) -TETRAHYDROCARBAZOLES | |
| DE1568734C3 (en) | N-dialkyl-aminoalkyl-S-diphenylsulfoximines and their salts and processes for their preparation | |
| DE1966215A1 (en) | Process for the preparation of heterocyclic benzamides | |
| DE2327193C3 (en) | N- (Diethylaminoethyl) -2-methoxy-5methylsulfonylbenzamide, its salts, processes for the preparation of these compounds and medicaments containing these compounds | |
| DE2140601A1 (en) | Derivatives of thiazolino pyrinidinon and process for their preparation | |
| DE1518311C (en) | N (2 diethylaminoethyl) 2 methoxy 3,4 or 4,5 methylenedioxybenzamide and their pharmacologically non-toxic acid addition salts | |
| DE1795110C (en) | N Substituted 2 methoxy 4,5 azimidobenzamides | |
| DE1111209B (en) | Process for the preparation of a new phenylalkylolamine with antitussive properties | |
| DE1235310B (en) | Process for the production of nopinic acid derivatives | |
| DE2221281B2 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects |